GNbAC1

Drug Profile

GNbAC1

Alternative Names: GENHP-01; GNN001

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator GeNeuro
  • Class Monoclonal antibodies
  • Mechanism of Action Toll-like receptor 4 antagonists; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 07 Dec 2016 GeNeuro plans the ANGEL-MS extension study for Multiple Sclerosis in Europe
  • 18 Dec 2015 Phase-II clinical trials in Multiple sclerosis (Second-line therapy or greater) in Ukraine, Spain, Serbia, Hungary, Hungary, Poland, Germany, Estonia, Czech Republic, Croatia (IV) (EudraCT2015-004059-29) (NCT02782858)
  • 01 Aug 2015 GeNeuro Innovation completes a phase I trial in Multiple Sclerosis (In volunteers) in Germany (NCT02452996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top